Open main menu

Psychiatrienet β

Sertraline-tranylcypromine

Revision as of 08:09, 21 October 2015 by Anoek (talk | contribs)
Sertraline
Type Antidepressant
Group SSRI
links
Medscape Sertraline
PubChem 68617
PubMed Sertraline
Kompas (Dutch) Sertraline
Wikipedia Sertraline
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine

Switch medication from sertraline to tranylcypromine.[1] [2]

Nietinrijdenbord.png Stop sertraline
  • Before day 1: gradually reduce dosage of sertraline to a maximum of 25 mg/day, when this dosage is > 25 mg/day.
  • Day 1: stop administration of sertraline.
Eenrichtingbord.png Start tranylcypromine
  • Day 1-14: a wash-out period of 2 weeks is necessary.
  • Day 15: start tranylcypromine the next day in a low dosage of 20 mg/day for one week.
  • Day 22: after this week the dosage of tranylcypromine can be increased gradually.
Letopbord.png Cave
Infobord.png More information
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.